The sigma enigma: In vitro / in silico site-directed mutagenesis studies unveil σ1 receptor ligand binding

Biochemistry

Volumn 53, Issue 18, 2014, Pages 2993-3003

  Brune, S ^a   Schepmann, D ^a   Klempnauer, K H ^a   Marson, D ^b   Dal Col, V ^b   Laurini, E ^b   Fermeglia, M ^b   Wunsch B ^a   Pricl, S ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MEMBRANES; THREE DIMENSIONAL;

INDIRECT EFFECTS; INTEGRAL MEMBRANE PROTEINS; LIGAND-BINDING SITES; NATURAL LIGANDS; RECEPTOR SYSTEM; RECEPTOR-LIGAND BINDING; SITE DIRECTED MUTAGENESIS; THREE-DIMENSIONAL STRUCTURE;

LIGANDS;

DELTA 1 RECEPTOR; DNA; MEMBRANE PROTEIN; PENTAZOCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; COMPUTER MODEL; FIBROBLAST CULTURE; GENE AMPLIFICATION; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUAIL; RECEPTOR BINDING ASSAY; SITE DIRECTED MUTAGENESIS;

BINDING SITES; COMPUTER SIMULATION; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PENTAZOCINE; RECEPTORS, SIGMA;

EID: 84900532376     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi401575g     Document Type: Article

References (42)

1. Matsumoto, R. R., Liu, Y., Lerner, M., Howard, E. W., and Brackett, D. J. (2003) Sigma receptors: Potential medications development target for anti-cocaine agents Eur. J. Pharmacol. 469, 1-12
2. Gilbert, P. E. and Martin, W. R. (1976) The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 197, 517-532
3. Gundlach, A. L., Largent, B. L., and Snyder, S. H. (1985) Phencyclidine and sigma opiate receptors in brain: Biochemical and autoradiographical differentiation Eur. J. Pharmacol. 113, 465-466
4. Hayashi, T. and Su, T. P. (2004) Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders CNS Drugs 18, 269-284
5. Fontanilla, D. 2009, The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator Science 323, 934-937
6. Hanner, M. 1996, Purification, molecular cloning, and expression of the mammalian sigma1-binding site Proc. Natl. Acad. Sci. U.S.A. 93, 8072-8077
7. Kekuda, R., Prasad, P. D., Fei, Y. J., Leibach, F. H., and Ganapathy, V. (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1) Biochem. Biophys. Res. Commun. 229, 553-558
8. Maurice, T. and Su, T. P. (2009) The pharmacology of sigma-1 receptors Pharmacol. Ther. 124, 195-206
9. Cobos, E. J., Entrena, J. M., Nieto, F. R., Cendan, C. M., and DelPezo, E. (2008) Pharmacology and therapeutic potential of sigma1 receptor ligands Curr. Pharmacol. 6, 344-366
10. Ishikawa, M. and Hashimoto, K. (2010) The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases J. Recept., Ligand Channel Res. 3, 25-36
11. Collina, S. 2013, Sigma receptor modulators: A patent review Expert Opin. Ther. Pat. 23, 597-613
12. Choi, S. R. 2001, Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent Nucl. Med. Biol. 28, 657-666
13. Tu, Z. 2007, Fluorine-18-labeled benzamide analogues for imaging the σ2 receptor status of solid tumors with positron emission tomography J. Med. Chem. 50, 3194-3204
14. 3H]-(+)-Pentazocine: A potent and highly selective benzomorphan-based probe for sigma-1 receptors Mol. Neuropharmacol. 3, 117-126
15. Okuyama, S. and Nakazato, A. (1996) NE-100: A novel sigma receptor antagonist CNS Drug Rev. 2, 226-237
16. 3H]SKF-10,047 binding sites (σ sites) exhibit a unique distribution in rat brain subcellular fractions Eur. J. Pharmacol., Mol. Pharmacol. Sect. 188, 211-218
17. Aydar, E., Palmer, C. P., Klyachko, V. A., and Jackson, M. B. (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit Neuron 34, 399-410
18. Russ, W. P. and Engelman, D. M. (2000) The GXXXG motif: A framework for transmembrane helix-helix association J. Mol. Biol. 296, 911-919
19. Seth, P. 2001, Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor Biochim. Biophys. Acta 1540, 59-67
20. 125I)iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor Proc. Natl. Acad. Sci. U.S.A. 89, 1393-1397
21. Laurini, E. 2011, Homology model and docking-based virtual screening for ligands of the σ1 receptor ACS Med. Chem. Lett. 2, 834-839
22. Laurini, E. 2012, Another brick in the wall. Validation of the σ1 receptor 3D model by computer-assisted design, synthesis, and activity of new σ1 ligands Mol. Pharmaceutics 9, 3107-3126
23. Yamamoto, H. 1999, Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding FEBS Lett. 445, 19-22
24. Palmer, C. P., Mahen, R., Schnell, E., Djamgoz, M. B. A., and Aydar, E. (2007) Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines Cancer Res. 67, 11166-11175
25. Pal, A. 2008, Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the α-1 receptor J. Biol. Chem. 283, 19646-19656
26. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent J. Biol. Chem. 193, 265-275
27. Woolf, T. B. and Roux, B. (1996) Structure, energetics, and dynamics of lipid-protein interactions: A molecular dynamics study of the gramicidin A channel in a DMPC bilayer Proteins 24, 92-114
28. Jo, S., Kim, T., and Im, W. (2007) Automated builder and database of protein/membrane complexes for molecular dynamics simulations PLoS One 2, e880
29. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 79, 926-935
30. Skjevik, Å. A., Madej, B. D., Walker, R. C., and Teigen, K. (2012) LIPID11: A modular framework for lipid simulations using Amber J. Phys. Chem. B 116, 11124-11136
31. Duan, Y. 2003, Point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 24, 1999-2012
32. 1 receptor J. Med. Chem. 55, 8047-8065
33. Laurini, E., Dal Col, V., Wünsch, B., and Pricl, S. (2013) Analysis of the molecular interactions of the potent analgesic S1RA with the σ1 receptor Bioorg. Med. Chem. Lett. 23, 2868-2871
34. Rossi, D. 2013, Chemical, Pharmacological, and in vitro Metabolic Stability Studies on Enantiomerically Pure RC-33 Compounds: Promising Neuroprotective Agents Acting as σ1 Receptor Agonists ChemMedChem 8, 1514-1527
35. Case, D.-A., (2012) Amber 12, University of California, San Francisco.
36. Ryckaert, J. P., Ciccotti, G., and Berendsen, H. J. C. (1977) Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes J. Comput. Phys. 23, 327-341
37. Srinivasan, J., Cheatham, T. E., III, Cieplak, P., Kollman, P. A., and Case, D. A. (1998) Continuum solvent studies of the stability of DNA, RNA and phosphoramidate-DNA helices J. Am. Chem. Soc. 120, 9401-9409
38. Laurini, E. 2013, Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments Mol. Oncol. 7, 968-975
39. Onufriev, A., Bashford, D., and Case, D. A. (2000) Modification of the generalized Born model suitable for macromolecules J. Phys. Chem. B 104, 3712-3720
40. Feig, M. 2004, Performance comparison of generalized Born and Poisson methods in the calculation of electrostatic solvation energies for protein structures J. Comput. Chem. 25, 265-284
41. http://www.esteco.com/home/mode-frontier/mode-frontier.html.
42. Chu, U. M., Ramachandran, S., Hajipour, A. R., and Ruoho, A. E. (2013) Photoaffinity Labeling of the Sigma-1 Receptor with N-[3-(4-Nitrophenyl)propyl]- N-dodecylamine: Evidence of Receptor Dimers Biochemistry 52, 859-868